• Home Dutch
  •  EN 
  • Employee login

Individual therapy response to a sodium-glucose transport inhibitor

Print 
Title:  Individual therapy response to a sodium-glucose transport inhibitor
Investigator:  Sergei Petrykiv 
Supervisor:  Hiddo Lambers Heerspink 
Promotor:  Dick de Zeeuw 
Summary:   Previous studies have shown a large variability in response to various anti-albuminuric drugs including ACE-inhibitors, Angiotensin Receptor Blockers, Direct renin inhibitors, NSAIDs, and endothelin antagonists. Very few studies have prospectively investigated whether this response variability is a random phenomenon due to biological or measurement variability or a ‘true’ variability in drug response. This project aims to prospectively study the between patient and within patient variability in response to a sodium-glucose-cotransport inhibitor dapagliflozin. 
Financing:  UMCG / Abbvie 
Start:  1-03-2014 
End: 01-03-2017
   
Projects
The use of a multiple parameter response efficacy score to predict the effect of a drug on hard renal and cardiovascular
Diabetes Mellitus Treatment for Renal Insufficiency Consortium (DIAMETRIC) database 
System biology approach for discovery of biomarkers of renal disease progressioni in diabetes (SysKid)
PROVALID – prospective multinational cohort study in patients with type 2 diabetes treated in primary care
Vitamin-D deficiency as a risk marker for renal and CV complications in the general population
A novel approach of personalized medicine: considering multiple effects of a single drug
Optimal hard endpoints in clinical trials of renal disease progression
Albuminuria as surrogate endpoint in clinical trials
Individual therapy response to a sodium-glucose transport inhibitor
Involving patients in the assessment and evaluation of medication treatment
Groningen Initiative to Analyse Type-2 diabetes Treatment ( GIANTT )
The role of medication adherence in predicting treatment response and estimating cost-effectiveness of statin treatment
Pharmacogenetics and response to treatment of oral antidiabetics
Quality of prescribing: patient specific indicators that predict better outcomes in diabetes patients
Quality assessment of pharmacotherapy in patients with chronic kidney disease
Cost effectiveness of ACEi and ARBs on renal failure in diabetes patients
Drug information and risk communication in Africa
Regulatory Science Projects